The purpose of the trial is to determine whether MK-8748 is at least as effective as aflibercept in preserving or improving vision. Participants will receive a series of injections into the eye over the course of about one year, with regular visits for eye checks, vision testing, and imaging that may involve the fluorescein dye.

Vision is measured using best-corrected visual acuity, which is the sharpest vision possible with the best glasses or contacts, and the results are recorded as letters on an ETDRS chart, a standard eye‑test chart. Throughout the study, doctors will monitor participants for any side effects or safety concerns.

People in the study are assigned by chance to receive either inclisiran or placebo, and neither the participants nor the study team knows which one is given. The study follows participants over time while they receive the injections and are checked regularly for major heart-related problems such as myocardial infarction (heart attack), ischemic stroke (stroke caused by a blocked blood vessel), death from heart disease, or urgent procedures to open blocked heart arteries. The main purpose of the study is to find out whether inclisiran lowers the risk of these serious events better than placebo.

People in the study will receive either VMX-C001 or the usual care used for this situation. Some participants may also receive heparin, another blood-thinning medicine, if planned by the treating team. The study is designed to compare the two approaches during the procedure and shortly afterward, without changing the urgent care needed for the surgery or procedure.

The study is a Phase 3 trial, which means it is being done in a larger group of people to better understand how well the treatment works and how safe it is. People taking part are assigned by chance to receive either nipocalimab or placebo. The treatment is given over time, and the study team follows participants through the treatment period to observe how the disease changes.

The purpose of the study is to see if MET097 helps participants lose more weight than the placebo after about 64 weeks. Throughout the trial, participants will visit the clinic regularly for weight checks, safety assessments, and blood tests, including a measurement of HbA1c, a test that shows the average blood‑sugar level over the past two to three months. Additional evaluations will monitor changes in cholesterol, blood pressure, and overall health status, and the study will continue with follow‑up visits for up to roughly 84 weeks.

The purpose of the study is to see if ziltivekimab works better than placebo in reducing the risk of serious heart-related problems in people who have both cardiovascular disease and kidney disease along with signs of inflammation in their body. The main focus is on preventing major cardiovascular events, which include death from heart-related causes, non-fatal heart attack, and non-fatal stroke. A heart attack occurs when blood flow to part of the heart muscle is blocked, while a stroke happens when blood flow to part of the brain is interrupted.

During the study, participants will receive either ziltivekimab or placebo through regular injections while continuing their standard medical treatment. The study will track various health outcomes over time, including heart attacks, strokes, heart-related deaths, hospital admissions for heart problems, and changes in kidney function. Researchers will also monitor changes in inflammation markers in the blood, heart function measurements, and overall health status. The study will measure how the kidneys are working by looking at blood test results that show the filtering ability of the kidneys and the amount of protein in the urine, which can indicate kidney damage.

The purpose of the study is to find out whether adding ianalumab to the usual treatment leads to a better disease response than placebo, using the SRI-4 score at week 60 as the main measure. Participants are randomly assigned to receive either the drug or placebo for about a year, with regular clinic visits for safety checks and disease assessments while they continue their regular medicines; the dose of steroids may be lowered if the disease improves.

Researchers will record how many participants show improvement in disease activity, avoid serious flare‑ups, and are able to reduce steroid use to 5 mg per day or less. They will also monitor for side effects and collect blood samples to check drug levels and any immune reaction against the drug. The study ends after the 60‑week treatment period, followed by a short follow‑up phase.

People in the study are assigned by chance to receive either KAI-9531 or placebo, and neither the participants nor the study team know which one is being given during the trial. Treatment is given over a long period, with regular study visits while the injections continue. The purpose of the study is to understand the efficacy and safety of KAI-9531 in people living with obesity or overweight and diabetes.

During the study, body weight, blood sugar, and other health measures are checked over time. The study also looks at possible side effects and at whether the body makes antibodies, which are proteins the immune system can form against a medicine. This information helps show how the treatment works and how safe it is for people taking it.

The purpose of this study is to see how effective Plozasiran is at reducing triglyceride levels in people with severe hypertriglyceridemia. Participants in the study will receive either Plozasiran or a placebo and will be monitored over a period of 12 months. During this time, the study will measure changes in triglyceride levels and monitor for any side effects. The goal is to determine if Plozasiran can significantly lower triglyceride levels compared to the placebo.

Participants will receive regular injections and attend scheduled visits to track their progress. The study aims to provide valuable information on the safety and effectiveness of Plozasiran, which could lead to new treatment options for people with severe hypertriglyceridemia. This research is important for understanding how to better manage this condition and improve patient outcomes.

The purpose of the study is to evaluate how well AVP-786 works in reducing agitation symptoms in patients with Alzheimer’s-related dementia. Participants in the study will receive either the AVP-786 medication or a placebo. The study is designed to be “double-blind,” meaning neither the participants nor the researchers will know who is receiving the actual medication or the placebo, to ensure unbiased results.

Throughout the study, participants will take the medication in capsule form by mouth. The study will last for a set period, during which participants will be monitored for any changes in their symptoms and any side effects they may experience. The goal is to determine if AVP-786 can help manage agitation in patients with Alzheimer’s-related dementia more effectively than a placebo.

The main goal of the study is to see how well CagriSema works at lowering blood sugar levels compared to semaglutide alone, as measured by a blood test called HbA1c that shows average blood sugar over several months. The study will also look at how these medications affect body weight, blood pressure, cholesterol levels, and other health measurements. Researchers want to understand if the combination medication works better than the individual medications at helping people reach target blood sugar levels and lose weight. The study will also measure how much time blood sugar levels stay within a healthy range using a continuous glucose monitor, which is a small device that tracks sugar levels throughout the day.

Participants will receive their assigned treatment for 68 weeks, with the entire study lasting about 75 weeks. During this time, they will have regular visits to check their blood sugar, weight, blood pressure, and overall health. The study will also ask participants questions about their quality of life and satisfaction with their diabetes treatment. Safety will be carefully monitored throughout the study, including checking for side effects and episodes of low blood sugar, which can occur when blood sugar drops too low and may cause symptoms like shakiness or confusion.

Participants in this study will be randomly assigned to receive either ivonescimab or bevacizumab, both given in combination with FOLFOX chemotherapy. The study is designed so that neither the participants nor their doctors will know which treatment is being given, which helps ensure fair comparison of the results. The medications will be given through a vein, which means they are delivered directly into the bloodstream through an intravenous line. During the study, participants will have regular check-ups where doctors will monitor the size of tumors using imaging scans and assess how well the treatment is working. The study will also track any side effects that occur and measure the levels of ivonescimab in the blood at different times.

The study will also collect information about how long participants live overall, how many people respond to treatment, and how long those responses last. Doctors will monitor for any unwanted effects from the medications and check blood tests for abnormal results. For those receiving ivonescimab, the study will also check whether the body develops antibodies against this medication, which could affect how well it works. This study is intended for people who have not yet received treatment for their metastatic colorectal cancer, though previous treatment for earlier stages of the disease is allowed if it was completed more than twelve months before the cancer spread.

The purpose of the study is to find out if adding Saruparib to the standard treatment of radiotherapy and androgen deprivation therapy can help men with this type of prostate cancer live longer without the cancer spreading to distant parts of the body compared to placebo. The study will measure how long participants remain free of distant spread of cancer, which is called metastases-free survival, and will also look at overall survival and other measures of how well the treatment works. During the study, participants will receive the study medication in tablet form taken by mouth, and they will need to have various scans including computed tomography or magnetic resonance imaging, bone scans, and prostate-specific membrane antigen-positron emission tomography scans to check for any signs of cancer spread.

Participants will be randomly assigned to receive either the active study medication or placebo in addition to their standard treatment, and neither the participants nor their doctors will know which treatment they are receiving during the study. The study requires tissue samples from the prostate cancer to confirm the presence of the BRCA gene mutation before enrollment. Throughout the study, participants will be monitored for how the treatment affects their cancer, their overall health, and their quality of life through questionnaires about symptoms and daily functioning. Blood samples will also be collected to measure the levels of the study medication in the body and to understand how it works.

The study involves two groups of participants – one receiving rocatinlimab injections under the skin along with topical treatments, and another receiving placebo injections with the same topical treatments. The treatment period lasts for 24 weeks, during which the effectiveness of the medication will be evaluated by examining improvements in skin appearance and reduction in disease severity.

Throughout the study, doctors will monitor how well the treatment works by checking if participants’ skin becomes clearer and if their symptoms, such as itching and skin pain, improve. They will pay special attention to how the treatment affects different areas of the body, including the face and hands, in people who have atopic dermatitis in these locations.

The purpose of this study is to find out if ziltivekimab works better than placebo in reducing the risk of death from heart and blood vessel problems and preventing heart failure events such as hospital stays or urgent visits for worsening heart failure. The study will also look at other health outcomes including the combined risk of death from heart problems, heart attacks, and strokes, as well as how the treatment affects kidney function, quality of life, and inflammation levels in the body. Quality of life will be measured using questionnaires that ask about symptoms and daily activities.

During the study, participants will receive monthly injections for up to 48 months. The study will track various health events including hospitalizations for heart failure, deaths, heart attacks, strokes, and changes in heart and kidney function. Blood tests will be done to measure inflammation markers like hs-CRP and heart stress markers like NT-proBNP. Heart function will be checked using echocardiography, which is an ultrasound test that creates pictures of the heart. The study will continue until enough information has been collected to determine whether ziltivekimab is effective in helping people with this type of heart failure and inflammation.

Participants in this study will be assigned to receive either MET097 or a placebo. The study is designed to compare how much body weight changes over a specific period of time. During the course of the trial, individuals will receive their assigned treatment once every week. The process involves monitoring weight changes and other health factors over a long period, extending up to 84 weeks, to observe the impact of the medication on overall health.

During the study, participants will receive either the new implant or the standard injection. The process involves monitoring changes in best corrected visual acuity, which refers to the clearest vision a person can achieve with glasses or contact lenses. Researchers will also observe changes in the thickness of the retina and how well participants can read letters on an eye chart over a period of time. The study will track how often additional treatments are required and how the swelling in the eye responds to the different options provided.

The purpose of the study is to evaluate how the body processes the medication and to monitor its safety. Researchers will observe how the drug is absorbed into the bloodstream, how it moves throughout the body, and how it is eventually eliminated. Additionally, the study will track how the body reacts to the treatment to ensure it is safe for use in this age group.

Participants will be assigned to receive either olpasiran or a placebo through a subcutaneous injection, which means the medication is delivered into the fatty tissue just under the skin. During the study, researchers will monitor for various health events such as ischemic stroke, which is a blockage of blood flow to the brain, and cardiovascular death. The study will also track changes in the levels of lipoprotein (a) in the blood over time to see how the treatment affects this substance.

During the study, participants will be monitored over a period of time to see how the medication affects the occurrence of major health events. These events include myocardial infarction, commonly known as a heart attack, stroke, or being hospitalized due to heart failure. The study also looks at coronary revascularization, which is a procedure used to improve blood flow to the heart, and any deaths caused by any reason.

During the study, participants may receive inclisiran via a subcutaneous injection, which is a needle shot just under the skin, or a placebo. In addition to the study medication, participants will continue to take background treatments, which include medications like rosuvastatin or atorvastatin. These are types of statins used to manage cholesterol levels. The study will monitor various changes in blood levels, including PCSK9, apoB, VLDL, and triglycerides, to understand how the treatment affects the body over time.

The course of the study involves monitoring participants from the time they are in the hospital through a period of 150 days. Medical professionals will observe how the different treatments influence cholesterol levels and check for any side effects that may occur during the treatment period.

The purpose of the study is to see how well Tirzepatide works compared to Dulaglutide in reducing major cardiovascular events, such as heart attacks or strokes, in people with Type 2 Diabetes who are at high risk for heart problems. Participants in the study will receive either Tirzepatide or Dulaglutide, along with their usual diabetes care, to see which treatment is more effective in preventing these serious heart-related events.

The study will take place over a period of time, during which participants will receive regular injections of either Tirzepatide or Dulaglutide. The researchers will monitor the participants’ health to track any occurrences of heart-related events. The goal is to determine if Tirzepatide is not only as effective as Dulaglutide but also if it might be superior in preventing major cardiovascular events in people with Type 2 Diabetes.

The trial has two parts. The first part is a safety run-in phase where a small group of patients will receive BNT113 combined with pembrolizumab to check if the combination is safe and well-tolerated. The second part is a randomized phase where patients will be assigned by chance to receive either the combination of BNT113 and pembrolizumab or pembrolizumab alone. During the trial, doctors will monitor how the cancer responds to treatment and will check for any side effects. Patients will need to have regular visits, blood tests, and scans to see how well the treatment is working.

The trial will measure several outcomes including how long patients live, how long it takes before the cancer grows or spreads, and whether the cancer shrinks or disappears. Doctors will also carefully track any side effects that occur during treatment. The trial will use imaging scans to measure changes in tumor size and will follow patients for up to several years to gather information about the long-term effects of these treatments.

The purpose of this study is to find out if camizestrant, either alone or combined with abemaciclib, works better than standard hormone treatments, either alone or combined with abemaciclib, in preventing breast cancer from coming back. The study will measure how long people remain free from invasive breast cancer returning. People taking part in this study will be assigned by chance to receive either camizestrant or one of the standard hormone treatments. The treatment will continue for a period of time, and people will be monitored regularly to check how well the treatment is working and to watch for any unwanted effects.

During the study, doctors will check for any side effects that occur, perform blood tests, and measure vital signs like blood pressure and heart rate. People in the study will also be asked questions about their quality of life and how the side effects of treatment affect them in their daily lives. Blood samples may be taken to measure the amount of camizestrant in the blood. The study will track whether the cancer comes back, spreads to other parts of the body, or if a new cancer develops, as well as overall survival.

The purpose of this study is to find out whether zilebesiran can reduce the risk of serious heart-related problems compared to placebo when added to standard blood pressure treatment. The study will look at whether the medication can prevent major events such as death from heart problems, heart attacks, strokes, or episodes of heart failure that require urgent medical attention or hospital admission. Heart failure is a condition where the heart cannot pump blood effectively enough to meet the body’s needs.

During the study, participants will receive injections of either zilebesiran or placebo while continuing their regular blood pressure medications. The study will measure blood pressure readings at regular visits and will track any heart-related health events that occur over time. Participants will be followed for several years to determine whether the treatment helps prevent serious cardiovascular problems. The study will also monitor how well the medication lowers blood pressure and whether it affects the risk of different types of heart and blood vessel complications.

The purpose of the study is to find out if XC001 can reduce the amount of heart muscle that does not receive enough blood after bypass surgery, and to assess whether it can improve how well the heart contracts and pumps blood. The study will use a special type of imaging called cardiovascular magnetic resonance imaging, which creates detailed pictures of the heart while it is under stress to show areas that are not getting enough blood flow. The study is designed to last 26 weeks, with an additional 26-week extension period for those who continue. Patients will be randomly assigned to receive either XC001 or placebo during their bypass surgery, and neither the patients nor the doctors will know which treatment is given until the study is completed.

After the bypass surgery, patients will undergo imaging tests at several time points to measure changes in blood flow to the heart and how well the heart is functioning. The first imaging will be done a few days after surgery to establish a starting point, and then additional imaging will be performed at 12 weeks and 26 weeks after surgery. For those who participate in the extension period, another imaging test will be done at 52 weeks. Throughout the study, doctors will monitor the safety of the treatment and track any side effects or complications that may occur. The study will compare the results between patients who received XC001 and those who received placebo to determine if the gene therapy provides any benefit in improving blood flow to areas of the heart that could not be fully treated by bypass surgery alone.

The purpose of the study is to compare how well BNT323 works against the doctor’s choice of chemotherapy in stopping the cancer from getting worse or spreading. The study will measure how long patients live without their cancer growing or spreading, and how long patients survive overall. The study will also look at how many patients have their tumors shrink or disappear, how long these responses last, and what side effects occur with each treatment. Patients will be assigned to one treatment or the other by chance, similar to flipping a coin, and both the patients and their doctors will know which treatment is being given.

During the study, patients will receive their assigned treatment for up to six months, and they will be monitored regularly with scans and tests to see how their cancer is responding and to check for any side effects. The study will track whether the cancer grows or spreads, and doctors will use specific measurement criteria to evaluate the size and extent of the tumors throughout the treatment period. The information gathered will help determine whether BNT323 is more effective than standard chemotherapy for treating this type of recurring uterine cancer.

The treatment plan involves giving medications before surgery (neoadjuvant therapy) to shrink the tumor. The study medications are given through an intravenous infusion directly into the bloodstream. Some participants will receive the new combination with sacituzumab tirumotecan, while others will receive standard chemotherapy which may include doxorubicin, epirubicin, or cyclophosphamide. All participants will also receive dexamethasone to help manage side effects, and some may receive capecitabine as part of their treatment.

The main purpose of this research is to determine whether the new treatment combination is more effective at eliminating cancer cells before surgery compared to standard chemotherapy. The study will also track how long participants remain free of cancer after treatment and monitor their overall survival. Researchers will carefully watch for any side effects and evaluate how the treatments affect participants’ quality of life.

The treatment involves taking AP31969 tablets orally for a period of 12 weeks. The medication will be provided as film-coated tablets in various dosage strengths. Some participants will receive the active medication, while others will receive placebo tablets that look identical to the real medication but contain no active substance.

During the study, participants will have their heart rhythm monitored continuously through special recording devices. The study will track how often atrial fibrillation episodes occur and how long they last. Participants will also complete questionnaires about their quality of life and symptoms related to their heart condition.

The study tests whether olpasiran is more effective than a placebo in reducing the risk of serious heart-related events. These events include coronary heart disease death, myocardial infarction (heart attack), and emergency procedures to restore blood flow to the heart. The medication is being studied specifically in people who have high levels of lipoprotein(a) in their blood and are considered at risk for heart problems.

During the study, participants will receive either olpasiran or a placebo while continuing their usual heart medications. The study will track any heart-related events that occur and measure how the treatment affects the amount of lipoprotein(a) in the blood. This research is part of a larger program called OCEAN(a)-PreEvent, which aims to better understand how to prevent first-time heart problems in people with high lipoprotein(a) levels.

The purpose of this research is to determine how well AZD0780 works compared to placebo in lowering LDL cholesterol levels after 12 weeks of treatment. The medication comes as a film-coated tablet that is taken by mouth. Some participants will receive AZD0780, while others will receive a placebo.

The study will last for 52 weeks (one year), during which participants will continue taking their regular cholesterol-lowering medications. Throughout the study, researchers will measure various types of cholesterol and other blood fats, including apolipoprotein B, non-HDL cholesterol, and lipoprotein(a), to understand how well the treatment works.

The purpose of this research is to determine if AZD0780 can reduce the risk of serious cardiovascular events such as heart attacks, strokes, and problems with blood flow to the legs in people with cardiovascular disease. The medication will be tested in addition to patients’ regular cholesterol-lowering treatments.

During the study, participants will receive either AZD0780 or a placebo for up to 54 months. The study team will monitor participants for any cardiovascular events, including heart-related death, heart attacks, strokes, severe leg circulation problems, and emergency procedures to restore blood flow. Throughout the study, participants will continue their usual heart medications, including their regular cholesterol-lowering treatments.

The medication is given as a solution for injection under the skin (subcutaneous use). During the study, participants will receive either maridebart cafraglutide or placebo. The study will track important heart-related events that may occur, such as heart attacks, strokes, and the need for heart procedures.

The research team will monitor participants’ health throughout the study, focusing particularly on heart and blood vessel-related events. The study will look at whether the medication can help prevent serious heart problems and improve survival rates in people who have both cardiovascular disease and weight issues.

The study will test whether a medication called vicadrostat (BI 690517) when used in combination with another medication called empagliflozin is better than empagliflozin alone (with placebo) for treating heart failure. The purpose of the study is to determine if this combination therapy can reduce the occurrence of cardiovascular death, hospitalizations for heart failure, or urgent heart failure visits.

Participants in this study will be randomly assigned to receive either the combination of vicadrostat and empagliflozin or empagliflozin with placebo. The study will track outcomes such as cardiovascular events and measure heart failure symptoms using a questionnaire. This is a double-blind study, which means neither the participants nor the researchers will know which treatment each participant is receiving during the study.

The purpose of this study is to evaluate how different doses of COR-1167 compare to a placebo in treating worsening heart failure. COR-1167 is a Corticotrophin Releasing Factor 2 Agonist, which is a type of medication being investigated for its potential to help the body eliminate excess fluid and improve heart function. The medication will be given as a daily subcutaneous injection (under the skin) for 4 weeks.

During the study, researchers will monitor several factors including: how much urine participants produce (natriuresis), changes in body weight, levels of certain heart failure markers in the blood (NT-proBNP), heart failure symptoms using a questionnaire, and measurements of heart structure (specifically the Left Atrial Volume Index, which indicates how much the upper left chamber of the heart is enlarged). The study will also evaluate the safety of the medication by monitoring for side effects and checking laboratory values.

The purpose of the study is to evaluate whether EYE103 is as effective as ranibizumab in improving vision in people with Diabetic Macular Edema. Participants in the study will receive either EYE103 or ranibizumab over a period of time, and their vision will be monitored to see how it changes. The study will last for about a year, with regular check-ups to assess the effects of the treatment.

During the study, participants will have their vision tested using a standardized chart called the ETDRS chart, which helps measure changes in vision clarity. The study aims to determine if EYE103 can provide similar benefits to ranibizumab in terms of improving vision over the course of the study. This research is important for finding effective treatments for people with Diabetic Macular Edema and improving their quality of life.